Different strategies to investigate quantitatively various indexes of human immunodeficiency virus type 1 (HIV-1) activity in vivo have recently been planned and developed (10, 14, 20, 21, 27, 28, (30) (31) (32) . Currently, several technical aspects (6, 8, 9) indicate that competitive PCR (cPCR) is the method of choice for the quantitative detection of both viral and eukaryotic nucleic acids present at low concentration in biological samples. In this context, cPCR and competitive reverse transcription (cRT)-PCR procedures have been planned, optimized (19, 23, 26) , and used to test clinical samples from HIV-1-infected patients at the different clinical phases of this infection (2, 3, 7, 24) . Overall, the results of these quantitative in vivo studies indicated that a significant association exists between levels of viral activity and disease progression, suggesting that quantitative molecular methods could be a powerful tool for a better understanding of the natural history of the infection and AIDS pathogenesis. Nonetheless, the availability of quantitative methods that provide insight into previously unchecked virological and molecular aspects of HIV-1 infection in vivo has also supplied a theoretical basis for specific antiretroviral treatments. Furthermore, principally due to the considerable plasticity of the HIV-1 genome that enables this virus to escape the host's immune response or to generate drug-resistant viral mutants during specific antiviral treatments, the precise evaluation of the efficacy of anti-HIV-1 therapy requires direct quantitative assay systems.
In this study, we aimed to evaluate the adaptability and reliability of cPCR-based techniques to monitor the effect of specific antiretroviral treatments on HIV-1 expression and replication directly in infected patients. Sequential clinical samples from treated patients were used in this study, and different virological parameters (HIV-1 genomic RNA copy number in plasma [HIV-1 viremia], late HIV-1 transcript copy number in peripheral blood mononuclear cells [PBMCs] , HIV-1 proviral copy number in PBMCs, and mean transcriptional activity [RNA/DNA ratio; HIV-1-specific late transcript copy numbers per each provirus copy number]) were assayed at each time point in samples from HIV-1-infected patients treated with azidothymidine (AZT) or ddI. Finally, the ability of quantitative molecular methods used in this study to provide information on the selection of drug-resistant viral mutants was also assayed by direct sequencing of the HIV-1 gene pol from cell-free plasma virions from three patients with documented rebound of viral load.
MATERIALS AND METHODS
Patients, clinical specimens, and nucleic acid purification. Sequential clinical samples were collected from 12 HIV-1-infected patients (8 males and 4 females; mean age, 29.5 years [range, 24 to 33 years]). The risk factors associated with HIV-1 infection were distributed as follows: intravenous drug addiction, eight subjects; homosexual activity, three subjects; heterosexual contact with a HIV-1-infected partner, one subject. The patients (four Centers for Disease Control and Prevention [CDC] class II, five CDC class III, and two CDC class IV patients and one patient who progressed from class III to IV during treatment) were studied at the beginning of antiretroviral therapy (time zero) with specific anti-HIV-1 compounds (AZT, ddI, and ddC) and monitored for 213 to 791 days during therapy.
Peripheral blood samples (EDTA treated) were centrifuged over a Ficoll density gradient. Plasma samples were recovered from the upper phase, and PBMCs were recovered from the top of the Ficoll layer after centrifugation. PBMCs were washed three times with phosphate-buffered saline. To clear the platelets and cell debris, the plasma was centrifuged again (3,000 ϫ g for 10 min). One milliliter of this supernatant was diluted in 9 ml of RPMI 1640 (Whittaker, Walkersville, Md.) and ultracentrifuged at 150,000 ϫ g for 1 h in a swingout rotor (Kontron Instruments, Milan, Italy). RNA samples were extracted from the virion pellet and PBMC pellet by using the guanidinium thiocyanate method, as previously described (1), and to minimize unintegrated DNA contamination, DNA samples were extracted from the nuclei of PBMCs (1) .
cPCR and cRT-PCR. cPCR and cRT-PCR procedures (2, 19) were used to analyze the following HIV-1-specific substrates directly and quantitatively: viral genomic RNA from plasma, virus-specific late transcripts from PBMCs, and proviral DNA from cell nuclei. Briefly, competitive analysis was performed by using plasmid pSKAN (19) ; this plasmid is a derivative of plasmid pBS (Stratagene, La Jolla, Calif.) in which the gag fragment with an 18-bp deletion (internal to the primer binding sites) is inserted downstream from the T3 RNA polymerase promoter. Competitor RNA was obtained after linearization of pSKAN and transcription in vitro; the competitor was then purified, treated with DNase (Bethesda Research Laboratories, Inc., Gaithersburg, Md.), and quantified by spectrophotometric reading, gel electrophoresis, and endpoint dilution followed by Poisson analysis of positive scores. Each RNA sample (10 l, equivalent to 100 l of plasma or 200,000 PBMCs) was reverse transcribed along with 2 l of increasing copy numbers (50 to 6,250) of competitor RNA and amplified as previously described (2); DNA samples (20 l, equivalent to 100,000 nuclei) were amplified in reaction tubes containing 10 l of the competitor plasmid pSKAN at increasing copy numbers (20 to 2,500). The amplification profile (15 s of denaturation at 94ЊC, 15 s of annealing at 60ЊC, and 45 s of extension at 72ЊC) was repeated for 50 cycles by using a GeneAmp PCR System 9600 (Perkin-Elmer Cetus, Norwalk, Conn.). All RNA and DNA samples were tested in a series of four different reactions. For competition analysis, 5 l of each 100-l reaction sample was run on a 10% polyacrylamide gel and analyzed after ethidium bromide staining, as previously described (2, 3, 19) .
Direct sequencing of the HIV-1 gene pol from cell-free plasma virions. The 769-bp fragment of the HIV-1 pol gene (in which mutations relevant to the development of AZT and ddI resistance occur) was specifically amplified, using the primers polA and polNE1 (13, 17, 19) (Fig. 1) . Briefly, 10 l of each RNA sample (equivalent to 100 l of plasma) maintained at Ϫ80ЊC after nucleic acid purification, and in which the amount of genomic molecules was previously determined by cRT-PCR, was reverse transcribed for 15 min at 42ЊC in a final volume of 20 l containing 100 U of Moloney murine leukemia virus reverse transcriptase (Bethesda Research Laboratories), 40 U of RNasin (Boehringer Mannheim), 20 pmol of polNE1 primer, 0.2 mM (each) deoxynucleoside triphosphates, 1ϫ PCR buffer (50 mM KCl, 10 mM Tris-HCl [pH 8.3], 1.5 mM MgCl), and DEPC-treated water. The viral cDNA was denatured for 5 min at 94ЊC, and 1ϫ PCR buffer containing 80 pmol of primer polNE1, 100 pmol of primer polA, and 2.5 U of Taq DNA polymerase was added. The PCR profile (denaturation for 30 s at 94ЊC; annealing for 30 s at 40ЊC, and extension for 90 s at 72ЊC) was repeated for 50 cycles in a GeneAmp PCR System 9600 (Perkin-Elmer Cetus) followed by a final incubation at 72ЊC for 10 min; the PCR product was analyzed with a 1% agarose gel in Tris-borate buffer. In some instances, the 769-bp RT-PCR product was subjected to further PCR amplification, using the following internal primer pairs to obtain an adequate amount of product for direct sequencing: pol4 and polC (position 5Ј-3Ј 2,596 to 2,619 and 2,913 to 2,893 of the AIDS-associated retrovirus type 2 (ARV2) nucleotide sequence, respectively) (25) , and polD and polE (position 5Ј-3Ј 3,034 to 3,052 and 3,255 to 3,239, respectively) ( Fig. 1) . Amplification with primers pol4 and polC generates a 318-bp fragment in which mutations determining changes at amino acid residues 24 to 112 of reverse transcriptase protein can be analyzed; nested PCR using primers polD and polE gives a 222-bp-long product in which mutations occurring at amino acid residues 167 to 267 can be recognized. Briefly, 10 l of DNA obtained after RT-PCR were reamplified in a mixture (final volume, 100 l) containing 1ϫ PCR buffer, 0.2 mM (each) deoxynucleoside triphosphates, 100 pmol of each primer, and 2.5 U of Taq DNA polymerase. The reactions were subjected to 50 amplification cycles (15 s at 94ЊC, 15 s at 50ЊC, and 60 s at 72ЊC, using primers pol4 and polC; 15 s at 94ЊC, 15 s at 45ЊC, and 60 s at 72ЊC, using primers polD and polE) followed by a final incubation at 72ЊC for 10 min. The products generated by RT-PCR (and in some cases by nested PCR) were separated electrophoretically through a Tris-acetate gel of 2% Nusieve; DNA was than rescued from the gel (by cutting the specific ethidium bromidestained band), extracted with phenol-chloroform, precipitated with 2 volumes of ethanol-Na-acetate (1/10, vol/vol), and dried under vacuum.
Sequencing reactions of double-stranded PCR products were performed directly, as previously described (18) , by the chain termination method, using a Sequenase kit (U.S. Biochemicals, Denver, Colo.) with minor modification; the samples were heat denatured (90ЊC for 3 min) in the presence of 10% dimethyl sulfoxide and the sequencing primer and quickly cooled in dry ice for 60 s. The labeling reaction was carried out at room temperature for 1 min; the termination reaction was carried out at 37ЊC for 3 min. Ten percent dimethyl sulfoxide was added to both labeling and termination mixtures. After the sequencing products were separated on a denaturing 6% polyacrylamide gel, the gels were washed, dried, and autoradiographed. Furthermore, to rule out the possibility that mutations could be introduced by the PCR assay, sequencing reactions were performed twice and bidirectionally for all samples from independently amplified products.
Statistical analysis of data. Statistical analysis of quantitative data was performed with the nonparametric Mann-Whitney-Wilcoxon test.
RESULTS
Molecular monitoring of HIV-1 activity during antiviral therapy. We studied a group of 12 HIV-1-infected patients under treatment with AZT (six patients [ Table 1 ]) and ddI (two patients [ Table 2 ]) or in whom treatment had been discontinued (one patient treated with AZT from days 1 to 394 and then with AZT and ddC; two patients treated with AZT for 230 and 660 days, respectively, and then with ddI; and one patient who received AZT for 170 days and interrupted the therapy from days 170 to 632 [ Table 3] ).
The molecular data show the dynamics of viral activity during specific antiretroviral therapy (Tables 1 to 3 ). In fact, an early fall in levels of cell-free (genomic) HIV-1 RNA copy numbers is evident for almost all patients (Fig. 2) . In several patients with high basal viremia levels, a dramatic drop of viral load was observed within 14 to 17 days (Table 1 , patients A02 and A03; Table 2 , patient D02; Table 3 , patients X01, X03, and X04); in some of these patients (A03, X01, and X04), the early decrease of viremia levels was paralleled by a fall in transcript copy numbers and mean transcriptional activity (RNA/DNA ratio). The decrease in proviral molecules per 10 5 PBMCs was delayed compared with the viremia level or transcript copy numbers; at the same time, CD4
ϩ T-cell counts generally failed to indicate any significant change during treatment, with only a few exceptions (patients A05, A06, and D01).
In seven cases (Table 1, patients A01, A03, A05, and A06;  Table 3 , patients X01, X02, and X04), a clear rebound of viremia levels was seen during the observation period; in most of these patients, a rebound to viremia levels higher than those observed before therapy was seen after 80 to 296 days, strongly suggesting that selection of drug-resistant HIV-1 strains occurred in these patients. Similarly, an evident rebound of HIV-1 viremia was observed in one patient (Table 3 , patient X03) who interrupted AZT therapy at day 170. Interestingly, molecular parameters of viral activity other than HIV-1 viremia (specific HIV-1 transcript molecules in PBMCs, proviral DNA molecules, and mean viral transcriptional activity) generally paralleled the time course of cell-free genome copy numbers in plasma; however, in most of these treated patients, the RNA parameters (cell-free viral genomes per milliliter of plasma and viral transcripts per 2 ϫ 10 5 PBMCs) seem to be highly sensitive indexes of the efficacy of a given antiretroviral compound. Finally, in several patients under therapy with AZT or ddI (patients A01, A02, A03, A04, D02, X01, and X04), sharp changes in viral activity levels were not paralleled by an evident modification of CD4 ϩ T-lymphocyte number per cubic millimeter of blood.
A statistical analysis of changes in viral load (genome copy numbers per milliliter of plasma) was performed in 11 of the 12 patients under treatment with AZT or ddI (patient X02 received AZT for 6 months during the year before the first evaluation [time zero] and was excluded from this analysis). The Mann-Whitney-Wilcoxon test employed for nonparametric statistical comparison of quantitative values at time zero (baseline) and after 4 to 13 weeks shows a significant change of HIV-1 genome copy number (P ϭ 0.00032) and transcript molecules in PBMCs (P ϭ 0.023) but not of HIV-1 proviral DNA (P ϭ 0.106). Additionally, in 7 of the 11 patients (indentified as patients A01, A03, A05, A06, X01, X02, and X04) who continued antiviral treatment during the period under study (patient X03 interrupted AZT therapy at day 170), a rebound of viral load was observed; the comparison between the baseline level of the genome copy number (HIV-1 viremia) and that determined in the last control (after 35 to 71 weeks from time zero) shows a significant increase (P ϭ 0.023) in 
Selection of drug-resistant HIV-1 mutants in patients with documented rebound of viral load.
We evaluated the correlation between the rebound of plasma viremia and the appearance of drug-resistant mutants in HIV-1-infected, treated patients. Sequencing analysis of a portion of the HIV-1 gene pol was carried out in three of the five patients with documented rebounds of viremia levels during therapy and in one patient ( Table 2 , patient D02) in whom a low viral load was maintained during therapy for more than 15 months. The results of sequencing analysis are summarized in Table 4 . Two patients (A01 and A03) received AZT, 1 patient (X02) had received AZT before being switched to ddI, and one patient (D02) was treated with ddI. In all cases, the first and the last samples available were assayed; sequential samples from patient X02 were analyzed from the time AZT was stopped and therapy was continued with ddI. This patient received AZT for 3 months 1 year before the first evaluation; interestingly, FIG. 1. The presence of mutations relevant to the development of resistance to AZT and ddI was evaluated by sequence analysis of a fragment of the HIV-1 gene pol. A 769-bp fragment of pol was amplified with primers polA and polNE1 (in some instances, this sequence was further amplified with internal primer pairs [pol4 and polC or polD and polE]; see Materials and Methods). Sequencing reactions of double-stranded PCR products were determined directly by the chain termination method, using primers polF, pol6, polG, and pol7. aa, amino acid(s); WT, wild type; nt, nucleotide(s); ARV2, AIDS-associated retrovirus type 2.
mutations at positions 41 (Met3Leu) and 215 (Thr3Phe and Tyr) (Table 4) were already selected at this time. At day 112 from the beginning of ddI therapy, a mutation at position 74 (Leu3Val; consistent with resistance to ddI) appeared as a mixed genotype population; this mutation became predominant 1 month later. Furthermore, a mutation at position 41 was seen in the last sample from patient A03, and in patients A03 and X02 a change at codon 39 (Thr3Ala; significance not investigated) was also detected. Mutations at positions 67 (Asp3His) and 70 (Lys3Arg) were documented in the last sample from patient A01, who received AZT for 13 months. Importantly, in this patient the maintenance of the wild-type genotype during the first 8 months of therapy parallels the decreased viremia levels. Similarly, a wild-type genotype was seen in samples from patient D02; in this patient, a reduced viral load was maintained during the observation period (455 days of therapy with ddI). Overall, mutations in at least two codons of the HIV-1 gene pol were documented in three patients whose viral loads (evaluated by cRT-PCR) increased during specific antiretroviral therapy.
DISCUSSION
In this study, different parameters of HIV-1 activity were monitored in patients under therapy with specific antiretroviral compounds. The data shown here confirm and extend recent observations that the molecular techniques employed in this study may efficiently be used for complete virological and clinical monitoring of treated HIV-1-infected patients. Importantly, although HIV-1 gene pol sequences were analyzed in only 5 of 12 patients, the results suggest that the processes of emergence and selection of drug-resistant HIV-1 mutants may be revealed with cRT-PCR.
Ideally, a method suitable for evaluating viral activity in vivo requires the characteristics of rapidity (the choice of a given therapeutic strategy may be dependent on the data obtained), flexibility (possibly different tissues or clinical specimens of different origin have to be used), high sensitivity and specificity, and finally, adaptability to absolute quantitation. Under these conditions, the advantages of using molecular methods appear to be evident, particularly in relationship to the genomic evolutionary potential documented for lentivirus infections (4, 11, 16) . In these infections, a mixture of distinct genomes (22) is generally detected, and not only antigenic properties (5) but also gene expression (15) , tissue tropism, pathogenicity, and drug resistance (13) of the infecting virus may change during the infection. In this context, it is reasonable to hypothesize that in vitro propagation of HIV-1 (viral isolation) increases the representation of the viral strains with a high replicative capacity, thus only approximating what is really occurring in vivo. Recently, we indicated that a cPCR-based strategy efficiently identifies those HIV-1-infected patients who (independently of clinical conditions) exhibit highly active infection (2) . Subsequently, an additional study with a cPCR-based approach was carried out; it evaluated the HIV-1 viremia of untreated and treated subjects at different phases of the infection (24) . Overall, the data suggested that this methodology may efficiently be used for not only studies of HIV-1 pathogenesis but also diagnostic applications, including monitoring of specific antiviral therapy. More recently (3), we documented that cRT-PCR-based techniques allow the dynamics of different virological parameters to be monitored for years in infected patients, thus obtaining a direct molecular profile of viral activity and replication during the various clinical phases of HIV-1 infection.
In the study presented here, we have specifically addressed the direct laboratory evaluation of therapy with specific anti-HIV-1 compounds at the molecular level. Using a cRT-PCR assay system, the degree of HIV-1 activity was evaluated in sequential samples from patients under treatment with antiretroviral compounds. Although the biochemistry of HIV-1 AZT and ddI resistance is not completely defined at present, AZT resistance was shown to be mediated by five amino acid substitutions in the viral reverse transcriptase protein (13, 17) ; similarly, resistance to ddI was found to be mediated by substitutions at codons 74, 69, and 184 (29) . Different aspects of the results shown here may have diagnostic and clinical importance. First, during the early phase of treatment with AZT and ddI, a significant drop of all parameters of HIV-1 activity could be detected in almost all patients; nonetheless, a residual (low) viral replication level was always documented. Second, of the different parameters monitored in these patients, the copy number of cell-free genomes in plasma (HIV-1 viremia) was a more sensitive index of the drugdependent fall in viral replication level than transcript (or provirus) copy numbers in PBMCs. Third, sequencing analysis of the HIV-1 gene pol suggests that the rebound of viral activity detected by the cPCR-based method employed in this study is associated with selection of drug-resistant viral mutants. This evidence may have medical importance, and it strongly indicates that quantitative molecular monitoring of treated patients by cRT-PCR represents a reliable strategy to evaluate directly in vivo the efficiency of a given antiviral therapy in any treated patient and at any time point. In fact, as observed in three patients who showed a rebound of HIV-1 viremia during therapy (Table 4) , emergence of viral strains bearing at least two mutations of the HIV-1 gene pol compatible with resistance to AZT or ddI were observed in cell-free plasma virus; in contrast, these mutations were undetectable in samples from a patient who maintained lowered HIV-1 viremia levels for 15 months during ddI therapy.
All patients included in this study received specific antiviral monotherapy. After an early phase of inhibition of viral replication, cRT-PCR indicated that this treatment was inefficient in a significant proportion of the subjects, as documented by a rebound of viremia levels. From this point of view, the molecular results may suggest that treatment with multiple compounds active at different steps of the viral replication cycle or on different virus-specific targets is necessary in this infection. Further molecular investigation of traditional and new therapeutic strategies for HIV-1-infected patients will be necessary to address this aspect, and cPCR-based methodology may represent an efficient laboratory tool for both in vitro and in vivo research.
